Sarah Steele and Lejla Sarcevic
Sarah Steele is a Senior Research Associate at Jesus College, and the Department of Politics and International Studies at the University of Cambridge. Having held posts at Barts and the London School of Medicine and Dentistry, the University of Cambridge, and the University of Oxford, among other institutions in the U.K., USA and Australia, Sarah is an experienced speaker, writer and researcher specializing in policy and public health analysis, as well as legal and qualitative research, as well as discourse analysis.
Lejla is a Forum Senior Research Associate at Jesus College, University of Cambridge. She is an investigative journalist and researcher, with a focus on corruption and tracking money and assets across borders and expertise in U.S. Freedom of Information requests. She worked on the Pulitzer Prize-winning Panama Papers – a leaked cache of documents which exposed the secretive offshore finance industry.
POPULAR
Shutdown deal buries federal food safety rules amid rising outbreaks
A funding bill to avert a government shutdown includes industry backed provisions that halt key FDA protections even as foodborne illnesses surge across the United States.
Epstein’s intelligence ties come into focus as Congress moves toward releasing government files
A growing body of evidence details Jeffrey Epstein’s extensive work with Israeli intelligence while lawmakers push to force public access to government records that have remained hidden for years.
Under Trump, rising costs are hitting families with $700 more per month
New Joint Economic Committee report shows inflation accelerating as White House withholds key CPI data.
Epstein & Israel: Drop Site News investigates Jeffrey Epstein’s ties to Israeli Intelligence
Drop Site revealed that Epstein had played a role in brokering a security agreement between Israel and Mongolia and setting up a backchannel between Israel and Russia during the Syrian civil war.
Human gene editing and the CRISPR revolution
CRISPR-based technology is advancing rapidly, driving international competition. Its promise to transform medicine is colliding with political and social realities, even as applications expand.